Related Experiment Video
Updated: May 14, 2025
08:20
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
6.6K
Exosome-Loaded GelMA Hydrogel as a Cell-Free Therapeutic Strategy for Hypertrophic Scar Inhibition
Hui Wang1,2, Xijuan Gao2, Yanxia Zhao2
1School of Nursing, Shandong Second Medical University, Weifang, People's Republic of China.
Clinical, Cosmetic and Investigational Dermatology
|May 12, 2025
Summary
This study developed an Exosome-Loaded GelMA Hydrogel (Exos-GelMA) for hypertrophic scar treatment. The Exos-GelMA hydrogel effectively inhibited scar formation by reducing collagen deposition and angiogenesis in a rabbit model.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Wound Healing Research
Background:
- Hypertrophic scarring (HS) results from abnormal wound healing, characterized by excessive extracellular matrix (ECM) deposition and angiogenesis.
- Current treatments for HS face challenges with efficacy and sustained drug delivery.
- Adipose-derived stem cell exosomes (ASCs-Exos) show promise for scar inhibition but require frequent application for optimal concentration.
Purpose of the Study:
- To develop and evaluate a novel injectable hydrogel system for sustained release of exosomes to modulate hypertrophic scars.
- To investigate the potential of Gelatin Methacryloyl (GelMA) hydrogel as a carrier for exosomes, leveraging its biomimetic properties and sustained release capabilities.
Main Methods:
- Fabrication and characterization of Exosome-Loaded GelMA Hydrogel (Exos-GelMA) for pore size and biocompatibility.
- Establishment of a rabbit ear hypertrophic scar model.
- Assessment of HS inhibition using histological staining (HE, Masson's trichrome) and immunohistochemical/immunofluorescence staining for Collagen I (COL I), Collagen III (COL III), α-smooth muscle actin (α-SMA), and vascular endothelial growth factor (VEGF).
Main Results:
- Exos-GelMA hydrogel exhibited suitable pore size, excellent biocompatibility, and promoted fibroblast proliferation in vitro.
- In the rabbit ear model, Exos-GelMA significantly reduced excessive collagen deposition and VEGF overexpression compared to the blank group.
- Quantitative analysis at 28 days showed significant reductions: COL I by 43%, COL III by 15%, α-SMA by 31%, and VEGF by 35% with Exos-GelMA treatment.
Conclusions:
- The Exos-GelMA composite hydrogel demonstrates significant potential for hypertrophic scar prevention and treatment.
- This study validates the feasibility of using Exos-GelMA as a cell-free therapeutic approach for managing hypertrophic scars.
